Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355084 | 0.83 | ALDH1A1 (0.43) | GAAALDH1A1SIGMAR1SMN1; SMN2KDM4E | |
| SCHEMBL6502976 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HTTSIGMAR1SMN1; SMN2MEN1 | |
| SCHEMBL31242949 | 0.81 | KDM4E (0.48) | GAAALDH1A1TDP1HTTSMN1; SMN2 | |
| SCHEMBL2004972 | 0.81 | SIGMAR1 (0.50) | ALDH1A1SIGMAR1SMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2008568 | 0.80 | SIGMAR1 (0.49) | ALDH1A1SIGMAR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31242833 | 0.80 | ALDH1A1 (0.45) | ALDH1A1TDP1KDM4EMEN1KMT2A | |
| SCHEMBL8290942 | 0.79 | ALDH1A1 (0.55) | GAAALDH1A1TDP1HTTSIGMAR1 | |
| SCHEMBL12304481 | 0.79 | SIGMAR1 (0.41) | ALDH1A1TDP1SIGMAR1KDM4EMEN1 | |
| SCHEMBL18322508 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL8290941 | 0.77 | ALDH1A1 (0.56) | GAAALDH1A1TDP1HTTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 269/4885ALDH1A1 2191/4885TDP1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.